Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New french questionnaire aims to catch Alzheimer's navigation trouble early

NCT ID NCT07616063

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a French questionnaire designed to identify spatial orientation problems in people with Alzheimer's disease. Researchers will ask 330 participants—including Alzheimer's patients, their caregivers, and healthy older adults—to fill out the questionnaire. The goal is to see if the tool is reliable and useful for spotting early signs of disorientation, which could lead to better care and support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Questionnaire d'Orientation Spatiale (QOS) - a French version of the Wayfinding Questionnaire
What this could lead to
If successful, this questionnaire could become a standard tool to detect spatial disorientation early in Alzheimer's, helping doctors provide better support.
What could go wrong
This is an early-stage validation study, not a treatment trial. The questionnaire may not prove accurate enough for routine use, and results may not apply outside French-speaking populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 330 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Alzheimer disease and their caregivers

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all subjects : * Native French speakers * Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale) * Person affiliated with a social security system or beneficiary of such a system Patients (Subgroup A1) and healthy control subjects (Group C): * Individuals who have received complete information about the clinical research organization and have signed their written informed consent * Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate Patients (group A): * Aged 55 to 85 * Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria) * Score of 4 or less on the Hachinski Ischemic Scale * Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination) * In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for \> 15 days * Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane Caregivers (group B): * Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week) * Healthy control subjects (group C): * Aged 55 to 85 * Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane * Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards Exclusion Criteria: For all subjects: * Adults subject to legal protection measures (guardianship, curatorship, judicial protection) * Adults unable to give their consent * Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1. * Persons capable of giving consent but unable to read French * Persons capable of giving consent but unable to write * One of the members of the patient/caregiver dyad refusing to participate in the study. Patients (subgroup A1) and healthy control subjects (group C): * Sensory or phasic deficit interfering with the task. * History of moderate or severe head trauma (with loss of consciousness). * Change in psychotropic treatment less than 48 hours before the tests * Chronic alcoholism * Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale) * Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Orientation, Spatial

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU (Centre Hospitalier Régionale Universitaire) Nancy

    Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.